According to PEHub :
“Cytovance® Biologics, Inc. (“Cytovance”), a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing company (CDMO), announced today that it has been acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. Through the Cytovance acquisition, Hepalink USA Inc. and its parent company Shenzhen Hepalink Pharmaceutical Co., Ltd. add a leading biologics CDMO to its current U.S. operations. Cytovance manufactures protein and antibody drugs for biotechnology and pharmaceutical companies throughout the world.
“This transaction expands our ability to develop and grow both our domestic and international businesses and will accelerate our current expansion plans in our Oklahoma City facilities,” said Mr. Darren Head, President and Chief Executive Officer of Cytovance. He added, “Great Point Partners has been an outstanding private equity partner that arranged debt financings enabling growth, helped us recruit senior executives, and that provided Dr. Bernhard Hampl, former CEO of Sandoz USA, from their CEO Advisory Board as Co-Chairman.”
The press release can be found here.